For research use only. Not for therapeutic Use.
Porgaviximab（Cat No.:I042086）is an investigational monoclonal antibody being developed for the treatment of viral infections, specifically targeting respiratory syncytial virus (RSV). It works by binding to the F protein of the RSV, preventing the virus from entering and infecting human cells. Porgaviximab is being studied as a potential therapeutic and prophylactic treatment option for RSV, particularly in high-risk populations such as infants, elderly individuals, and immunocompromised patients. Clinical trials are underway to assess its safety, efficacy, and ability to reduce the severity of RSV infections and prevent future occurrences.
| Catalog Number | I042086 |
| CAS Number | 1792982-55-8 |
| Purity | ≥95% |
